Isolated trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide

Substantially pure trans isomers of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide address drug resistance in cancer therapy by providing superior antiproliferative activity and stability, enhancing treatment efficacy.

JP2024541953APending Publication Date: 2024-11-13TYRNOVO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024525148
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-04
Filing Date
2022-10-03
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Current cancer treatments face challenges with drug resistance, necessitating the development of compounds with improved inhibitory properties against insulin receptor substrate (IRS) and signal transducer and activator of transcription 3 (Stat3) for enhanced therapeutic efficacy.

Method used

The development of substantially pure isolated trans isomers of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide, which exhibit improved antiproliferative activity and stability, reducing the risk of photoinduced isomerization and increasing bioavailability.

Benefits of technology

The trans isomer demonstrates enhanced potency against cancer cells, maintaining effectiveness in gastric and intestinal environments, and improves therapeutic outcomes compared to cis isomer or mixed isomer formulations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541953000014
    Figure 2024541953000014
  • Figure 2024541953000015
    Figure 2024541953000015
  • Figure 2024541953000016
    Figure 2024541953000016
Patent Text Reader

Abstract

The present invention discloses an isolated substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide, a process for its preparation, pharmaceutical compositions containing it, and its use in the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the isolated trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide and its use in the treatment of cancer. [Background technology]

[0002] Cancer is a common disease worldwide with a wide range of target sites in tissues. It is characterized by uncontrolled proliferation of cells as a result of various factors ranging from pollutants to genetic predisposition. Current cancer therapies include surgical interventions to remove solid tumors, as well as systemic cancer therapies using chemotherapeutic, hormonal, and immunotherapeutic agents. There are a variety of existing drugs that are effective in treating different types of cancer, but in many cases, cancers become resistant to drugs. Therefore, new therapeutic strategies are desirable.

[0003] WO 2008 / 068751 discloses compounds that have increased inhibitory properties of insulin-like growth factor 1 receptor (IGF1R), platelet derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR), and IGF1R-related insulin receptor (IR) activation and signaling.

[0004] WO 2009 / 147682 discloses compounds that act as protein kinase (PK) and receptor kinase (RK) signaling modulators. Further disclosed in WO 2009 / 147682 are methods for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and methods of using these compounds and compositions as chemotherapeutic agents, particularly for the prevention and treatment of PK- and RK-related disorders, such as metabolic, inflammatory, fibrotic, and cell proliferative disorders, in particular cancer.

[0005] WO 2012 / 117396 describes the combination of a compound of WO 2008 / 068751 or WO 2009 / 147682 with an anti-cancer agent for the treatment of cancer.

[0006] WO 2016 / 125169 describes combinations of compounds of WO 2008 / 068751 or WO 2009 / 147682 with (i) epidermal growth factor receptor inhibitors (EGFR inhibitors) and EGFR antibodies, (ii) inhibitors of the mammalian target of rapamycin (mTOR), (iii) mitogen-activated protein kinase (MEK) inhibitors, (iv) mutant B-Raf inhibitors, (v) immunotherapeutic agents, and (vi) chemotherapeutic agents for the treatment of cancer.

[0007] WO 2019 / 097503 relates to the treatment of cancer using a combination therapy comprising a dual modulator of insulin receptor substrate (IRS) and signal transducer and activator of transcription 3 (Stat3) in combination with an antibody against programmed cell death 1 (PD-1) protein, an anti-programmed cell death protein 1 ligand (PD-L1) antibody, or a combination thereof. This combination can be used to develop or resensitize tumors that have developed resistance to anti-PD-1 and / or anti-PD-L1 antibodies by enhancing tumor response to anti-PD-1 and / or anti-PD-L1 antibodies, converting unresponsive tumors to responsive ones, and / or blocking tumor progression.

[0008] 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide (compound 5), first disclosed in WO 2009 / 147682, is a dual modulator of insulin receptor substrate (IRS) and signal transducer and activator of transcription 3 (Stat3). It contains a double bond conjugated to a thioamide bridging between two catechol rings. WO 2009 / 147682 teaches that this compound, as well as other compounds disclosed therein, can be any structural and geometric isomer, including, inter alia, cis and trans isomers.

[0009] There is an unmet need for compounds with improved IRS and Stat3 inhibitory properties that are useful in the treatment of cancer. Summary of the Invention

[0010] The present invention provides a substantially pure isolated trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide, pharmaceutical compositions containing same, and uses thereof in the treatment of cancer.

[0011] It is now disclosed for the first time that the substantially pure trans-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide provides improved antiproliferative activity compared to cis and trans mixtures of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide. It is now disclosed for the first time that the substantially pure trans-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide exhibits superior octanol:water partition coefficients as well as thermal behavior compared to the cis-isomer, and these properties are indicative of its improved bioavailability. In contrast to conventional cis-trans stereoisomers that contain non-rotating double bonds, it has been unexpectedly found that the rotation of the double bond in 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide can occur freely upon exposure to light, thereby resulting in interconversion between trans and cis isomers in solution. It has been unexpectedly shown that the antiproliferative activity of the compound decreases with increasing content of cis isomer due to light-induced isomerization. Furthermore, it has been unexpectedly shown that the trans isomer is effective against cancer cells, while the trans-cis mixture is less effective at the same concentration. Thus, it is contemplated that the substantially pure trans isomer has improved bioavailability and increased efficacy in the treatment of cancer compared to the cis isomer or a trans-cis mixture containing more than 20% of the cis isomer.

[0012] According to a first aspect, the present invention provides a substantially pure trans-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide having the following structural formula:

[0013] [ka] or a pharma- ceutically acceptable salt thereof.

[0014] As used herein, and unless otherwise indicated, the term "substantially pure" refers to the compound 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide in the trans configuration substantially free of cis isomers. For example, in some embodiments, the substantially pure trans isomer of the compound comprises greater than about 80% by weight of the trans isomer of the compound and less than about 20% by weight of the cis isomer of the compound. In other embodiments, the substantially pure trans isomer of the compound comprises greater than about 85% by weight of the trans isomer of the compound and less than about 15% by weight of the cis isomer of the compound. In yet other embodiments, the substantially pure trans isomer of the compound comprises greater than about 90% by weight of the trans isomer of the compound and less than about 10% by weight of the cis isomer of the compound. In currently preferred embodiments, the substantially pure trans isomer of the compound comprises greater than about 95% by weight of the trans isomer of the compound and less than about 5% by weight of the cis isomer of the compound. In additional currently preferred embodiments, the substantially pure trans isomer of the compound comprises greater than about 97% by weight of the trans isomer of the compound and less than about 3% by weight of the cis isomer of the compound.

[0015] According to some embodiments, the present invention provides a pharmaceutical composition comprising as an active ingredient a substantially pure trans-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier or excipient.

[0016] In certain embodiments, the pharmaceutical composition is in the form of a solution, suspension, or emulsion. Each possibility represents a separate embodiment.

[0017] According to additional embodiments, the pharma- ceutically acceptable carrier or excipient is hydroxypropyl-β-cyclodextrin (HPCD). According to further embodiments, the weight ratio between the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide or a pharma- ceutically acceptable salt thereof and HPCD is from about 1:1 to about 1:12, including any ratio therebetween. According to certain embodiments, the weight ratio between the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide or a pharma- ceutically acceptable salt thereof and HPCD is from about 1:4 to about 1:8, including any ratio therebetween.

[0018] According to some embodiments, the pharmaceutical composition is protected from visible light. In a specific embodiment, the pharmaceutical composition is held in a device that is opaque to visible light. In a further embodiment, the light-opaque device has a light transmittance within the visible wavelength range of less than about 20%, preferably less than about 10%, more preferably less than about 5%.

[0019] According to other embodiments, the pharmaceutical composition is stored in a container that is opaque to visible light. In certain embodiments, the light-opaque container has a light transmittance within the visible wavelength range of less than about 20%, preferably less than about 10%, and more preferably less than about 5%.

[0020] According to further embodiments, the pharmaceutical composition is provided in a kit suitable for intravenous administration, the kit being opaque to visible light, hi specific embodiments, the light-opaque kit has a light transmittance within the visible wavelength range of less than about 20%, preferably less than about 10%, more preferably less than about 5%.

[0021] According to some embodiments, the pharmaceutical composition is protected from UV light. In a specific embodiment, the pharmaceutical composition is held in a device that is opaque to UV light. In a further embodiment, the light-opaque device has a light transmittance within the UV wavelength range of less than about 20%, preferably less than about 10%, more preferably less than about 5%.

[0022] According to other embodiments, the pharmaceutical composition is stored in a container that is impermeable to UV light. In certain embodiments, the light impermeable container has a light transmittance within the UV wavelength range of less than about 20%, preferably less than about 10%, and more preferably less than about 5%.

[0023] According to a further embodiment, the pharmaceutical composition is provided in a kit suitable for intravenous administration, the kit being opaque to UV light, hi a specific embodiment, the light-opaque kit has a light transmittance within the UV wavelength range of less than about 20%, preferably less than about 10%, more preferably less than about 5%.

[0024] According to some embodiments, the pharmaceutical composition is useful for treating cancer. In certain embodiments, the present invention provides a method of treating cancer, comprising administering to a subject in need of treatment a substantially pure trans isomer as disclosed herein or a pharmaceutical composition comprising the same. In other embodiments, the present invention provides a use of a substantially pure trans isomer as disclosed herein for the preparation of a medicament for treating cancer. In further embodiments, the cancer is selected from the group consisting of head and neck cancer, sarcoma, multiple myeloma, ovarian cancer, breast cancer, renal cancer, gastric cancer, hematopoietic cancer, lymphoma, leukemia, lung cancer, melanoma, glioblastoma, hepatocellular carcinoma, esophageal cancer, gastroesophageal junction cancer, prostate cancer, pancreatic cancer, and colon cancer. Each possibility represents a separate embodiment.

[0025] According to other embodiments, the substantially pure trans isomer of the present invention or a pharmaceutical composition comprising the same is co-administered in combination with an anti-cancer agent. According to some embodiments, the anti-cancer agent comprises at least one of: (i) a modulator of protein kinase (PK) selected from an epidermal growth factor receptor inhibitor (EGFR inhibitor) and an EGFR antibody; (ii) an inhibitor of mammalian target of rapamycin (mTOR); (iii) a mitogen-activated protein kinase (MEK) inhibitor; (iv) a mutant B-Raf inhibitor; (v) a chemotherapeutic agent; and (vi) an immunotherapeutic agent comprising an antibody against programmed cell death 1 (PD-1) protein, programmed cell death protein 1 ligand (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), or a combination thereof. Each possibility represents a separate embodiment. According to certain embodiments, the co-administration is performed simultaneously or sequentially in any order. Each possibility represents a separate embodiment.

[0026] According to additional embodiments, there is provided a method for preventing conversion of a substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide to the cis isomer, comprising maintaining the substantially pure trans isomer in a light-tight device or container, hi some embodiments, the light-tight device or container is substantially opaque to light in the UV-VIS wavelength range.

[0027] Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given hereinafter. It should be understood, however, that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

[0028] The present invention will be more fully understood from the following drawings and detailed description of the preferred embodiments thereof. [Brief description of the drawings]

[0029] [Figure 1] Chemical structure with atoms annotation of the trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide. [Diagram 2] Chemical structure with atoms annotation of the cis isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide. [Diagram 3] 1H NMR spectrum of trans and cis mixture of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide after UV light exposure. [Figure 4A] UV spectra (obtained from HPLC peaks) of the trans (4A) and cis (4B) isomers of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide. [Figure 4B] UV spectra (obtained from HPLC peaks) of the trans (4A) and cis (4B) isomers of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide. [Figure 5A] HPLC chromatograms of short-term stability study of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide solutions: (5A) Solution X1, (5B) Solution X2, (5C) Solution Y1, (5D) Solution Y2, (5E) Solution Z1, and (5F) Solution Z2. [Figure 5B]HPLC chromatograms of short-term stability study of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide solutions: (5A) Solution X1, (5B) Solution X2, (5C) Solution Y1, (5D) Solution Y2, (5E) Solution Z1, and (5F) Solution Z2. [Figure 5C] HPLC chromatograms of short-term stability study of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide solutions: (5A) Solution X1, (5B) Solution X2, (5C) Solution Y1, (5D) Solution Y2, (5E) Solution Z1, and (5F) Solution Z2. [Figure 5D] HPLC chromatograms of short-term stability study of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide solutions: (5A) Solution X1, (5B) Solution X2, (5C) Solution Y1, (5D) Solution Y2, (5E) Solution Z1, and (5F) Solution Z2. [Figure 5E] HPLC chromatograms of short-term stability study of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide solutions: (5A) Solution X1, (5B) Solution X2, (5C) Solution Y1, (5D) Solution Y2, (5E) Solution Z1, and (5F) Solution Z2. [Figure 5F] HPLC chromatograms of short-term stability study of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide solutions: (5A) Solution X1, (5B) Solution X2, (5C) Solution Y1, (5D) Solution Y2, (5E) Solution Z1, and (5F) Solution Z2. [Figure 6] Antiproliferative activity of solutions with different ratios of cis:trans isomers of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide in human melanoma A375 cells. [Figure 7A]Partition coefficient between water and octanol to determine the lipophilicity (LogP) of each isomer. (7A) HPLC chromatograms of the cis isomer in the octanol phase, (7B) the cis isomer in the aqueous phase, (7C) the trans isomer in the octanol phase, and (7D) the trans isomer in the aqueous phase. Equal volumes (13 μL) of each phase were analyzed. [Figure 7B] Partition coefficient between water and octanol to determine the lipophilicity (LogP) of each isomer. (7A) HPLC chromatograms of the cis isomer in the octanol phase, (7B) the cis isomer in the aqueous phase, (7C) the trans isomer in the octanol phase, and (7D) the trans isomer in the aqueous phase. Equal volumes (13 μL) of each phase were analyzed. [Figure 7C] Partition coefficient between water and octanol to determine the lipophilicity (LogP) of each isomer. (7A) HPLC chromatograms of the cis isomer in the octanol phase, (7B) the cis isomer in the aqueous phase, (7C) the trans isomer in the octanol phase, and (7D) the trans isomer in the aqueous phase. Equal volumes (13 μL) of each phase were analyzed. [Figure 7D] Partition coefficient between water and octanol to determine the lipophilicity (LogP) of each isomer. (7A) HPLC chromatograms of the cis isomer in the octanol phase, (7B) the cis isomer in the aqueous phase, (7C) the trans isomer in the octanol phase, and (7D) the trans isomer in the aqueous phase. Equal volumes (13 μL) of each phase were analyzed. [Figure 8A] Stability of cis and trans isomers in (8A) FASSGF and (8B) FASSIF media. [Figure 8B] Stability of cis and trans isomers in (8A) FASSGF and (8B) FASSIF media. [Figure 9A] Thermogravimetric spectra of (9A) the trans isomer and (9B) the cis isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide. (9C) Overlay of the spectra of the two isomers. [Figure 9B]Thermogravimetric spectra of (9A) the trans isomer and (9B) the cis isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide. (9C) Overlay of the spectra of the two isomers. [Figure 9C] Thermogravimetric spectra of (9A) the trans isomer and (9B) the cis isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide. (9C) Overlay of the spectra of the two isomers. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] The present invention relates to a substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide having the following structural formula:

[0031] [ka] or a pharma- ceutically acceptable salt thereof.

[0032] The present invention is further directed to a pharmaceutical composition comprising as an active ingredient the substantially pure trans-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier or excipient.

[0033] The present invention is further directed to a method of using the substantially pure trans-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising same, in treating cancer.

[0034] The present invention is based, in part, on the surprising discovery that the double bond in 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide can freely interconvert from the trans to the cis isomer when exposed to UV-VIS light, in contrast to conventional double bonds that do not allow for free interconversion between the cis and trans isomers. The substantially pure trans isomer exhibited high potency in inhibiting the proliferation of human melanoma A375 cells, while a mixture of both isomers exhibited lower potency in inhibiting A375 cell proliferation. Thus, the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide provides enhanced antiproliferative efficacy compared to mixtures containing both the trans and cis isomers. The substantially pure trans isomer was further characterized for its octanol:water partition coefficient, stability in biorelevant fluids, and thermal behavior. It is now disclosed for the first time that a substantially pure trans isomer is shown to be more stable in gastric and intestinal fluids and to exhibit improved bioavailability compared to the cis isomer.

[0035] In accordance with the principles of the present invention, the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide comprises at least 80% by weight of the trans isomer depicted in FIG. 1 and less than 20% by weight of the cis isomer depicted in FIG. 2. Preferably, the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide comprises at least 85% by weight of the trans isomer depicted in FIG. 1 and less than 15% by weight of the cis isomer depicted in FIG. 2. More preferably, the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide comprises at least 90% by weight of the trans isomer depicted in FIG. 1 and less than 10% by weight of the cis isomer depicted in FIG. 2. Even more preferably, the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide comprises at least 95% by weight of the trans isomer depicted in Figure 1 and less than 5% by weight of the cis isomer depicted in Figure 2. Most preferably, the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide comprises at least 97% by weight of the trans isomer depicted in Figure 1 and less than 3% by weight of the cis isomer depicted in Figure 2.

[0036] The synthesis of the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide can be carried out as known in the art. Briefly, the synthesis includes the following steps: First, 2-bromo-3,4-dimethoxybenzaldehyde and malonic acid are reacted in a Knoevenagel condensation to give 2-bromo-3,4-dimethoxycinnamic acid. Second, 2-bromo-3,4-dimethoxycinnamic acid is then converted to an acyl chloride derivative, which is further reacted with 3,4,5-trimethoxybenzylamine to give 3-(2-bromo-3,4-dimethoxy-benzyl)-N-(3,4,5-dimethoxy-benzyl)-acrylamide. Third, Lawesson's reagent is then used as a thiolating agent to generate 3-(2-bromo-3,4-dimethoxy-benzyl)-N-(3,4,5-dimethoxy-benzyl)-thio-acrylamide from the previous compound. Finally, boron tribromide is used to cleave the methoxy protecting group to generate the final product.

[0037] According to some aspects and embodiments, the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide has physical properties such that it remains stable in a gastric environment for at least 2 hours. According to other aspects and embodiments, the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide has physical properties such that it remains stable in a gastric environment for at least 3 hours. According to yet other aspects and embodiments, the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide has physical properties such that it remains stable in a gastric environment for at least 4 hours. According to further aspects and embodiments, the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide has physical properties such that it remains stable in the intestinal environment for at least 2 hours. According to other aspects and embodiments, the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide has physical properties such that it remains stable in the intestinal environment for at least 3 hours. According to still other aspects and embodiments, the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide has physical properties such that it remains stable in the intestinal environment for at least 4 hours. As used herein, the term "stable" refers to a decrease in concentration of less than about 10% of the initial concentration.

[0038] The substantially pure trans isomers of the present invention may exist as their pharma- ceutically acceptable salts. The term "salts" encompasses both basic and acid addition salts, including, but not limited to, salts containing carboxylate or amine nitrogens, and includes salts formed with organic and inorganic anions and cations as discussed below. In addition, the term includes salts formed by standard acid-base reactions with basic groups (such as amino groups) and organic or inorganic acids. Such acids include hydrochloric acid, hydrofluoric acid, trifluoroacetic acid, sulfuric acid, phosphoric acid, acetic acid, succinic acid, citric acid, lactic acid, maleic acid, fumaric acid, palmitic acid, cholic acid, pamoic acid, mucic acid, D-glutamic acid, D-camphoric acid, glutaric acid, phthalic acid, tartaric acid, lauric acid, stearic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, sorbic acid, picric acid, benzoic acid, cinnamic acid, and the like. Each possibility represents a separate embodiment of the present invention.

[0039] The term "organic or inorganic cation" refers to the counterion of the anion of the salt. Counterions include, but are not limited to, alkali and alkaline earth metals (such as lithium, sodium, potassium, barium, aluminum, and calcium), ammonium, and mono-, di-, and tri-alkylamines, such as trimethylamine, cyclohexylamine, and organic cations, such as dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, bis(2-hydroxyethyl)ammonium, phenylethylbenzylammonium, dibenzylethylenediammonium, and the like. See, for example, Berge et al., J.Pharm.Sci.(1977), 66:1-19, which is incorporated herein by reference.

[0040] Within the scope of the invention is a pharmaceutical composition comprising a substantially pure trans isomer of the invention or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier or excipient. The pharmaceutical composition may be in the form of a liquid preparation, such as, but not limited to, a liquid solution, suspension, or emulsion, or in the form of a solid preparation, such as, but not limited to, a tablet, powder, capsule, or pellet. Each possibility represents a separate embodiment.

[0041] To avoid interconversion of substantially pure trans isomers to cis isomers, the pharmaceutical composition is preferably shielded from visible and / or UV light, for example, using a light-resistant device and / or container. Suitable light shielding is achieved using any of the following or a combination thereof: using amber containers (e.g., amber glass crimp-top vials), aluminum foil coverings, black plastic coverings, dark rooms, double-sleeve jackets, coated injection kits, etc. Each possibility represents a separate embodiment. Specifically, the light-resistant device, container, or covering has a light transmittance of less than about 20%, preferably less than about 10%, more preferably less than about 5% in the UV-VIS wavelength range.

[0042] Thus, the present invention further includes a method of preventing conversion of a substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide to the cis isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide, comprising maintaining the substantially pure trans isomer or a composition comprising same in a light-resistant device, container, or covering as detailed above. According to some embodiments, the light-resistant device, container, or covering is substantially impermeable to light within the UV-VIS wavelength range. The term "light-impermeable" as used herein refers to a device, container, or covering that at least partially or preferably completely prevents transmission of light within a wavelength range of about 100 to about 800 nanometers (nm), including each value within the specified range. In some embodiments, the light-opaque device, container, or covering at least partially or preferably completely prevents light transmission within the UV wavelength range of about 100 to about 400 nanometers (nm), including each value within the specified range. In other embodiments, the light-opaque device, container, or covering at least partially or preferably completely prevents light transmission within the visible wavelength range of about 400 to about 800 nanometers (nm), including each value within the specified range. Typically, the light transmission within the UV and / or visible range is less than about 20%, 15%, 10%, 5%, or 1%, with each possibility representing a separate embodiment.

[0043] Within the scope of the present invention is the optional inclusion of at least one pharma- ceutically acceptable carrier or excipient in the pharmaceutical compositions disclosed herein.Suitable pharma- ceutically acceptable carriers or excipients include, but are not limited to, diluents, preservatives, solubilizers, emulsifiers, adjuvants, and the like.Each possibility represents a separate embodiment. Such compositions may be liquid or lyophilized or otherwise dried formulations and may include diluents of various buffer contents (e.g., Tris-HCl, acetates, phosphates), pH and ion adjusting agents, additives such as albumin or gelatin to prevent absorption to surfaces, surfactants (e.g., Tween 20, Tween 80, Pluronic F68, bile salts), solubilizers (e.g., glycerol, polyethyleneglycerol), antioxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., thimerosal, benzyl alcohol, parabens), and bulking agents or tonicity adjusters (e.g., lactose, mannitol). Each possibility represents a separate embodiment.

[0044] Furthermore, as used herein, "pharmaceutically acceptable carriers" are well known to those skilled in the art and include, but are not limited to, 0.01-0.1M, preferably 0.05M phosphate buffer, or 0.8% saline. In addition, such pharmaceutically acceptable carriers can be aqueous or non-aqueous solutions, suspensions, and emulsions. Each possibility represents a separate embodiment. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions or suspensions, including saline and buffered media. Each possibility represents a separate embodiment.

[0045] Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Each possibility represents a separate embodiment. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives such as, for example, antibacterial agents, antioxidants, and the like may also be present. Each possibility represents a separate embodiment.

[0046] Controlled or sustained release compositions include formulation in lipophilic depots (e.g., fatty acids, waxes, oils).Also encompassed by the invention are particulate compositions coated with polymers (e.g., poloxamers or poloxamines) and protective coatings.

[0047] Pharmaceutically acceptable carriers may further include gums, starches, sugars, cellulosic materials, lactose, acacia, gelatin, alginic acid, stearic acid, or magnesium stearate, each possibility representing a separate embodiment.

[0048] Examples of suitable oily vehicles or solvents are vegetable or animal oils such as sunflower oil or fish-liver oil, petroleum, or oils derived from animals, vegetables, or synthetic sources, such as peanut oil, soybean oil, or mineral oil. Each possibility represents a separate embodiment. Examples of suitable water-based vehicles are water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycol or polyethylene glycol, glycerol, or ethanol. Each possibility represents a separate embodiment. In addition, if desired, the present compositions can contain minor amounts of auxiliary substances, such as wetting or emulsifying agents and / or pH buffering agents.

[0049] In a currently preferred embodiment, the pharmaceutical compositions disclosed herein contain a chelating agent. Suitable chelating agents within the scope of the present invention include, but are not limited to, cyclodextrins (modified or unmodified), such as, but not limited to, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin, sulfobutylether β-cyclodextrin, and mixtures or combinations thereof. Each possibility represents a separate embodiment. In a currently preferred embodiment, the chelating agent is hydroxypropyl-β-cyclodextrin (HPCD). Typically, the chelating agent, such as HPCD, is present in the composition in an amount that results in a weight ratio between the substantially pure trans isomer and HPCD of about 1:1 to about 1:12. Suitable weight ratios between the substantially pure trans isomer and HPCD within the scope of the present invention include, but are not limited to, about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:11, or about 1:12, with each possibility representing a separate embodiment. According to certain embodiments, the weight ratio between the substantially pure trans isomer and HPCD is from about 1:4 to about 1:8, e.g., about 1:6.

[0050] In accordance with the principles of the present invention, the substantially pure trans isomer or compositions containing same are useful for treating cancer.

[0051] Thus, the present invention provides a method of treating cancer comprising administering to a subject in need of treatment a therapeutically effective amount of the substantially pure trans-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide or a pharmaceutical composition comprising same.

[0052] A "therapeutically effective amount" as used herein refers to an amount of an agent that, upon administration to a subject in a single or multiple doses, is effective in providing a therapeutic benefit to the subject. In one embodiment, the therapeutic benefit is the treatment of cancer. The amount that will be therapeutically effective will depend on the nature of the disorder or condition and can be determined by standard clinical techniques. In addition, in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose employed will also depend on the route of administration, and the progression of the disease or disorder, and should be determined according to the judgment of the practitioner and each patient's circumstances. Preferred dosages will be in the range of 0.01 mg / kg to 1000 mg / kg body weight, 0.1 mg / kg to 100 mg / kg, 1 mg / kg to 100 mg / kg, 10 mg / kg to 75 mg / kg, 0.1 mg / kg to 1 mg / kg, etc., including each value within the specified range. Exemplary, non-limiting amounts include 0.1 mg / kg, 0.2 mg / kg, 0.5 mg / kg, 1 mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg, 50 mg / kg, 60 mg / kg, 75 mg / kg, and 100 mg / kg. Each possibility represents a separate embodiment.

[0053] Alternatively, the amount administered may be measured and expressed as a molar concentration of the compound administered. By way of example and not limitation, the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide may be administered in the range of 0.1-10 mM, e.g., 0.1, 0.25, 0.5, 1, and 2 mM. Each possibility represents a separate embodiment. Alternatively, the amount administered may be measured and expressed as mg / ml, μg / ml, or ng / ml. By way of example and not limitation, typical amounts include 1 ng / ml to 1,000 mg / ml, e.g., 1-1,000 ng / ml, 1-100 ng / ml, 1-1,000 μg / ml, 1-100 μg / ml, 1-1,000 mg / ml, 1-100 mg / ml, etc., inclusive of each value within the specified range. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test bioassays or systems.

[0054] The term "treatment of cancer" in the context of the present invention includes at least one of the following: a reduction in the rate of cancer growth (i.e., the cancer still grows, but at a slower rate), a halt in the growth of the cancer, i.e., tumor growth is stasis, and in favorable cases, the tumor is reduced or reduced in size. The term also includes a reduction in the number of metastases, a reduction in the number of new metastases formed, a slowdown in the progression of the cancer from one stage to another, and a reduction in angiogenesis induced by the cancer. In the most favorable cases, the tumor is completely eliminated. In addition, the term includes an increase in the survival time of the subject undergoing treatment, an increase in the time of disease progression, tumor regression, and the like. It should be understood that the term "treatment of cancer" also refers to the inhibition of malignant (cancer) cell growth, including tumor formation, primary tumor, tumor progression, or tumor metastasis. The term "inhibition of proliferation" with respect to cancer cells may further refer to a decrease in at least one of the following: a decrease in cell number compared to a control (due to cell death, which may be necrosis, apoptosis, or any other type of cell death, or a combination thereof), a decrease in the proliferation rate of the cells (i.e., the total number of cells may increase, but at a lower level or rate than in the control), a decrease in invasiveness of the cells compared to a control (e.g., as determined by a soft agar assay), even if the total number of cells remains unchanged, a progression from a less differentiated cell type to a more differentiated cell type, a slowing down of neoplastic transformation, or alternatively, a slowing down of the progression of cancer cells from one stage to the next.

[0055] The term "cancer" as used herein refers to disorders in which a population of cells becomes, to varying degrees, unresponsive to the control mechanisms that normally govern proliferation and differentiation. Cancer refers to various types of malignant neoplasms and tumors, including primary tumors and tumor metastases. Non-limiting examples of cancers that can be treated by the substantially pure trans isomer or pharmaceutical compositions comprising same are brain, ovarian, colon, prostate, kidney, bladder, breast, lung, oral cavity, and skin cancer. Each possibility represents a separate embodiment. Specific examples of cancers are carcinoma, sarcoma, myeloma, leukemia, lymphoma, and mixed tumors. Each possibility represents a separate embodiment. Particular categories of tumors include lymphoproliferative disorders, breast cancer, ovarian cancer, prostate cancer, cervical cancer, endometrial cancer, bone cancer, liver cancer, stomach cancer, colon cancer, pancreatic cancer, thyroid cancer, head and neck cancer, cancer of the central nervous system, cancer of the peripheral nervous system, skin cancer, kidney cancer, and metastases of all of the above. Each possibility represents a separate embodiment. Specific types of tumors include hepatocellular carcinoma, liver cancer, hepatoblastoma, rhabdomyosarcoma, esophageal cancer, thyroid cancer, glioblastoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endothelial sarcoma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, invasive ductal carcinoma, papillary adenocarcinoma, melanoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma (well-differentiated, moderately differentiated, poorly differentiated, or undifferentiated), renal cell carcinoma, adrenal tumor, adrenal-like adenocarcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, and testicular tumors, lung cancer, including small cell, non-small cell, and large cell lung cancer, bladder cancer, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, retinoblastoma, neuroblastoma, colon cancer, rectal cancer, hematopoietic malignancies, including all types of leukemia and lymphoma, including acute myeloid leukemia, acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mast cell leukemia, multiple myeloma, myeloid lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and hepatocellular carcinoma. Each possibility represents a separate embodiment.

[0056] In some exemplary embodiments, the cancer is selected from the group consisting of head and neck (H&N) cancer, sarcoma, multiple myeloma, ovarian cancer, breast cancer, renal cancer, gastric cancer, hematopoietic cancer, lymphoma, leukemia (including lymphoblastic leukemia), lung cancer, melanoma, glioblastoma, hepatocellular carcinoma, esophageal cancer, gastroesophageal junction cancer, prostate cancer, pancreatic cancer, and colon cancer. Each possibility represents a separate embodiment.

[0057] Routes of administration include, but are not limited to, oral, topical, transdermal, intra-arterial, intranasal, intraperitoneal, intramuscular, subcutaneous, intravenous, intratracheal, intrabronchial, intraalveolar, transmucosal, intraventricular, intracranial, and intratumoral. Each possibility represents a separate embodiment. The present invention further provides for administration of a substantially pure trans-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide in combination therapy with at least one additional anticancer agent. Such additional anti-cancer agents, in accordance with the principles of the present invention, include epidermal growth factor receptor inhibitors (EGFR inhibitors), including erlotinib, gefitinib, lapatinib, vandetanib, neratinib, icotinib, afatinib, dacomitinib, poziotinib, AZD9291, CO-1686, HM61713, and AP26113; EGFR antibodies, including trastuzumab, cetuximab, necitumumab, and panitumumab; rapamycin; mammalian target of rapamycin (mTOR inhibitors), including sirolimus, ridaforolimus (AP23573), NVP-BEZ235, everolimus (Afinitor, RAD-001), temsirolimus (CCI-779), OSI-027, XL765, INK128, MLN0128, AZD2014, DS-3078a, and Palomid529; trametinib (GSK1120212), selmetinib (GSK1120212), and selmetinib (GSK1120213). Mitogen-activated protein kinase inhibitors (MEK inhibitors), including binimetinib, binimetinib (MEK162), PD-325901, cobimetinib, CI-1040, and PD035901; mutant B-Raf inhibitors, including vemurafenib (PLX-4032), PLX4720, sorafenib (BAY43-9006), and dabrafenib; topoisomerase inhibitors, spindle poisons: vinblastine, vincristine, vincristine Chemotherapeutic agents, including sucrose, vinorelbine (Taxol), paclitaxel, docetaxel, and alkylating agents: mechlorethamine, chlorambucil, cyclophosphamide, melphalan, ifosfamide; methotrexate; 6-mercaptopurine; 5-fluorouracil, cytarabine, gemcitabine; podophyllotoxins: etoposide, irinotecan, topotecan; anticancer chemicals containing a quinone group: carbaziquinone;Antibiotics: doxorubicin (adriamycin), daunorubicin, idarubicin, epirubicin, bleomycin, mitomycin; nitrosoureas: carmustine (BCNU), lomustine; inorganic ions: cisplatin, carboplatin, and oxaliplatin; interferon, asparaginase; hormones: tamoxifen, leuprorelin, flutamide, and megestrol acetate. and pembrolizumab (Keytruda), nivolumab (Opdivo), AGEN-2034, AMP-224, BCD-100, BGBA-317, BI-754091, CBT-501, CC-90006, cemiplimab, GLS-010, IBI-308, JNJ-3283, JS-001, MEDI-0680, MGA-012, MGD-013, PDR-001, PF-06801591, REGN-2810, SHR-1210, TSR-042, LZM-009, ABBV-181, pidilizumab, avelumab (Bavencio), durvalumab (Imfinzi), atezolizumab (Tecentriq), BMS-936559, CX-072, SHR-1316, M-7824, LY-3300054, FAZ-053, Included are immunotherapeutic agents comprising an antibody against a target selected from the group consisting of programmed cell death protein 1 (PD-1), programmed cell death protein 1 ligand (PD-L1), and cytotoxic T-lymphocyte protein 4 (CTLA4), including KN-035, CA-170, CK-301, CS-1001, HLX-10, MCLA-145, MSB-2311, and MEDI-4736. Each possibility represents a separate embodiment;

[0058] Within the scope of the combination therapies of the present invention are combinations with immunotherapeutic agents that are antibodies against targets including any of the following: CD20, CD30, CD33, CD52, VEGF, and ErbB2. Each possibility represents a separate embodiment.

[0059] It is further contemplated that combination therapy includes two or more active ingredients in a single pharmaceutical composition as well as in two separate pharmaceutical compositions administered to the same subject simultaneously or at a time interval determined by the skilled artisan. For example, administration of the pharmaceutical composition disclosed herein can be performed before, after, or simultaneously with administration of the other anti-cancer agent. The other anti-cancer agent can be administered before the start of treatment with the pharmaceutical composition disclosed herein or after treatment with the pharmaceutical composition disclosed herein. In addition, the other anti-cancer agent can be administered during the administration period of the pharmaceutical composition disclosed herein, but need not occur throughout the entire treatment period. In another embodiment, the treatment plan includes pre-treatment with one agent, either the pharmaceutical composition disclosed herein or another anti-cancer agent, followed by the addition of one or more other agents. Alternating sequences of administration are also contemplated as known in the art.

[0060] As used in this specification and the appended claims, the term "about" refers to ±10%.

[0061] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, a reference to an "anticancer agent" includes a plurality of such agents. It should be noted that the term "and" or "or" is generally employed in its sense including "and / or" unless the context clearly dictates otherwise.

[0062] The principles of the present invention are illustrated by the following non-limiting examples. EXAMPLES

[0063] Example 1: Synthesis of the trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide All chemicals used in chemical synthesis were purchased from Sigma.

[0064] Synthesis of 2-bromo-3,4-dimethoxycinnamic acid

[0065] [ka] A catalytic amount of piperidine (0.2 equiv.) was added to a solution of 2-bromo-3,4-dimethoxybenzaldehyde (1 equiv.) and malonic acid (1.5 equiv.) in pyridine (4 ml / mmol aldehyde). The reaction mixture was heated to 120° C. for 6 h. The solution was cooled to 0° C. and concentrated HCl was added dropwise until pH<3. The precipitate was collected by filtration, washed with water, and dried under reduced pressure to give 2-bromo-3,4-dimethoxycinnamic acid as a white solid in 62% yield. 1 H NMR (400 MHz, CDCl3 + acetone-d6): δ 8.07 (d, J = 15.6 Hz), 7.45 (d, J = 8.8 Hz, 1H), 6.95 (d, J = 8.8 Hz, 1H), 6.31 (d, J = 15.6 Hz, 1H), 3.93 (s, 3H), 3.85 (s, 3H).

[0066] Synthesis of the trans isomer of 3-(2-bromo-3,4-dimethoxyphenyl)-N-(3,4,5-trimethoxy-benzyl)-acrylamide

[0067] [ka] Oxalyl chloride (4 equiv.) was added to a cooled solution of 2-bromo-3,4-dimethoxycinnamic acid (1 equiv.) in CHCl and the solution was stirred at room temperature for 1-2 h. Excess oxalyl chloride was distilled off and the mixture was evaporated to dryness. The residue was dissolved in CHCl and added dropwise to a cooled solution of 3,4,5-trimethoxybenzylamine (0.9 equiv.) and EtN (4 equiv.) in CHCl. ​​The reaction mixture was stirred at room temperature overnight (until TLC showed the disappearance of the amine) and then treated with water. CHCl was evaporated under reduced pressure and the residue was filtered and washed with ethyl acetate. The filtrate was extracted twice with ethyl acetate and the combined organic phases were dried over NaSO, filtered and the solvent was evaporated to give a brown solid. The crude solid was purified by flash chromatography (ethyl acetate / hexanes) to give 3-(2-bromo-3,4-dimethoxy-benzyl)-N-(3,4,5-trimethoxyphenyl-benzyl)-acrylamide in 55% yield as a white solid. 1 H NMR (400MHz, CDCl3): δ7.96(d,J=15.6Hz,1H),7.31(d,J=8.8Hz,1H),6.86(d,J=8.8Hz,1H),6.55(s,2H) ),6.28(d,J=15.6Hz,1H),5.91(bt,1H),4.50(d,J=5.6Hz,2H),3.90(s,3H),3.85(s,9H),3.84(s,3H).

[0068] Synthesis of the trans isomer of 3-(2-bromo-3,4-dimethoxyphenyl)-N-(3,4,5-trimethoxy-benzyl)-thioacrylamide

[0069] [ka] 3-(2-Bromo-3,4-dimethoxy-benzyl)-N-(3,4,5-trimethoxyphenyl)-acrylamide (1 eq.) and Lawesson's reagent (0.55 eq.) were refluxed in toluene for 3 h (until TLC showed disappearance of the amide). The reaction mixture was cooled to room temperature. The crude mixture was adsorbed onto silica gel and purified by column chromatography (ethyl acetate / hexanes) to give 3-(2-Bromo-3,4-dimethoxy-benzyl)-N-(3,4,5-trimethoxyphenyl)-thioacrylamide in 50% yield as a pale yellow solid. 1 H NMR (400MHz, CDCl3): δ8.05(d,J=15.6Hz,1H),7.45(bt,1H),7.33(d,J=8.8Hz,1H),6.86(d,J=8.8Hz,1H),6. 73(d,J=15.6Hz,1H),6.60(s,2H),4.89(d,J=5.2Hz,2H),3.91(s,3H),3.86(s,6H),3.85(s,3H),3.83(s,3H).

[0070] Synthesis of the trans isomer of 3-(2-bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide

[0071] [ka] Boron tribromide (2.5 equivalent excess for each methoxy group) was added to an ice-cold solution of 3-(2-bromo-3,4-dimethoxyphenyl)-N-(3,4,5-trimethoxy-benzyl)-thioacrylamide (approximately 20 ml / mmol) in CHCl. ​​The reaction mixture was allowed to warm to room temperature and stirred for 5 h. The solution was cooled to 0°C and then treated with cold water. DCM was evaporated and the solution was extracted three times with ethyl acetate. The combined organic layers were dried over NaSO and the solvent was evaporated under reduced pressure. The crude yellow product can be recrystallized from acetonitrile or crystallized by a solvent / antisolvent system of water / ethanol or acetone / chloroform to give 3-(2-bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide as yellow crystals in 50-60% yield. 1 H NMR (300MHz, CDCl3): δ4.77(d,2H,J=5.2Hz,CH2N),6.43(s,2H,aromatic),6.86(d,1H,J=8.4Hz,aromatic),7.01( d,1H,J=15.2Hz,alkene),7.16(d,1H,J=8.4Hz,aromatic),8.27(d,1H,J=15.2Hz,alkene),8.99(br.s.,1H,NH).

[0072] Example 2: Exposure of the trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide to UV light - 1 H NMR analysis A sample of the substantially pure trans-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide in 10% d6-DMSO in buffer (pH 7.4) was irradiated with artificial sunlight for 5 hours. The solution was then 1 The solution was characterized by H-NMR analysis. The solution showed significant conversion of the essentially pure trans isomer to the cis isomer, resulting in a mixture of trans and cis isomers. 1 The H-NMR spectrum is shown in FIG.

[0073] Table 1 was obtained for the cis and trans isomers of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide. 1 The H-NMR chemical shifts are summarized below. There are clear differences between the two isomers, especially in the double bond couplings (notes 8 and 9). HH The coupling of the trans isomer is 12.3 Hz, while the coupling of the trans isomer is 15.1 Hz. 1 H-NMR analysis can be used to distinguish between the two isomers.

[0074] [Table 1]

[0075] Example 3: Preparation of a formulation of the trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide in HPCD A formulation of the trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide in 2-hydroxypropyl-β-cyclodextrin (HPCD) (4 L, density 1.15 g / mL) was prepared in a 10 L glass double jacketed reactor equipped with a Teflon coated controlled speed agitator. In particular, 1,680 grams of HPCD was added to Water for Injection (WFI) (2,040 g) with mixing at 50° C. / approximately 250 RPM. The solution was cooled to room temperature after complete dissolution of the HPCD. 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide trans isomer (280 g) was added to the solution and mixed at room temperature under light-proof conditions until complete dissolution was achieved.

[0076] Additional WFI (600 g) was added to the solution while mixing at room temperature / approximately 250 RPM and protected from light to wash the inside of the reactor and complete the volume to a total of 2,640 g WFI in the formulation. The bulk solution was filtered and sterilized using a sterile and non-pyrogenic 0.22 μm filtration unit into a light-proof sterile container. The formulation was stored in an amber vial protected from light at −20° C. until use.

[0077] Example 4: Exposure of the trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide to light - UV analysis A solution of 100 mg / mL of the trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide dissolved in 600 mg / mL HPCD was diluted to a solution of 0.5 mg / mL of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide in 0.025% phosphoric acid and left on the bench in a clear glass vial exposed to room lighting for several days. Exposure resulted in the conversion of the trans isomer to the cis isomer. The UV spectra of the trans and cis isomers are shown in Figures 4A and 4B, respectively.

[0078] Example 5: Short-term stability of diluted formulations The stability of the trans isomer upon exposure to artificial sunlight was evaluated. The following solutions were prepared: D5W- (5% w / v dextrose in DDW): 5 g of dextrose was dissolved in 100 ml of DDW and filtered using a 0.22 μm filter.

[0079] Stock solution X- (1,000 mM solution in DMSO): 4.12 mg of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide was dissolved in 10 μL of DMSO. The stock solution was shown to contain 2.3% cis-isomer and 97.6% trans-isomer. Stock solution X was then diluted to a concentration of 3.6 mM of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide by adding 915 μL of D5W and further diluting 300 μL of the latter solution in 600 μL of D5W. The diluted solution was divided into two, one of which was stored at 4° C. and protected from light (solution X1) and the other was exposed to artificial sunlight at room temperature (approximately 20° C.) for 4 hours (solution X2).

[0080] Stock solution Y - A 70 mg / mL solution of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide in 420 mg / mL HPCD in water for injection was prepared by dissolving HPCD in water for injection and adding 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide as described in Example 3 (169.9 mM solution in HPCD). The stock solution was shown to contain 0.3% cis isomer and 99.1% trans isomer. The stock solution was then diluted to a concentration of 3.6 mM 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide by adding 42.4 μL of stock solution Y to 1,958 μL of D5W. The diluted solution was divided into two, one was stored at 4°C protected from light (solution Y1), and the other was exposed to artificial sunlight at room temperature (approximately 20°C) for 4 hours, then wrapped in aluminum foil and further stored at 4°C (solution Y2).

[0081] Stock solution Z- (10 mM solution in DMSO): 4.12 mg of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide was dissolved in 1 mL of DMSO. The stock solution was shown to contain 0.4% cis-isomer and 99.5% trans-isomer. The stock solution was then diluted to a concentration of 3.6 mM 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide by adding 300 μL of stock solution Z to 600 μL of D5W. The diluted solution was divided into two, one was stored at 4° C. protected from light (solution Z1) and the other was exposed to artificial sunlight at room temperature (approximately 20° C.) for 4 hours, then wrapped in aluminum foil and further stored at 4° C. (solution Z2).

[0082] HPLC analysis of the various solutions for determination of the cis to trans ratio was performed. The results are presented in Table 2 and Figures 5A-5F. In particular, Figures 5A, 5C, and 5E show the HPLC chromatograms of the solutions protected from light (Solution X1, Solution Y1, and Solution Z1, respectively), and Figures 5B, 5D, and 5F show the HPLC chromatograms of the solutions exposed to light for 4 hours (Solution X2, Solution Y2, and Solution Z2, respectively).

[0083] [Table 2]

[0084] The results show that significant conversion of the substantially pure trans isomer (Rt approx. 16.7 min) to the cis isomer (Rt approx. 15.0 min) is induced by light exposure.

[0085] An additional evaluation of the stability of the trans isomer upon exposure to artificial sunlight was performed. A solution containing 100% of the trans isomer at a concentration of 1 mM was exposed to 125 lux of light (1 lux of light is 1 lumen per square meter (lm / m)). 2 ) and the conversion to the cis isomer was determined by HPLC at different time points. The results are summarized in Table 3.

[0086] [Table 3]

[0087] Thus, approximately 50% conversion of the trans to cis isomer was detected after 1 h exposure to 125 lux light at 4° C. The conversion further progressed to 64% cis after 2 h exposure and to over 90% cis after 5 h exposure.

[0088] Example 6: Antiproliferative activity of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide isomers Test formulation A stock solution of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide was prepared by dissolving 1.5 mg of the compound in 1.8 mL of ethanol in a light-proof tube to give a 2 mM solution. 1.48 mL of the solution was then added to 2.52 mL of sterile DDW to provide a concentration of 0.74 mM (0.3 mg / mL) in 37% EtOH in water. The solution was divided into four tubes, and tube #0 was kept in the dark at 4° C. and wrapped in aluminum foil, while the other tubes were exposed to sunlight at room temperature for 1 h, 4 h, and 24 h, and were labeled #1, #4, and #24, respectively. The solutions were used for cell proliferation studies and further stored frozen for chemical analysis and wrapped in aluminum foil. The content of cis and trans isomers in each solution was analyzed using HPLC with special care from light.

[0089] cell culture A375 (malignant human melanoma) cells were purchased from ATCC (American Type Culture Collection). The cells were cultured and grown in RPMI 1640 medium (complete medium) supplemented with 10% fetal bovine serum, 1% glutamine, 1% penicillin, and 1% streptomycin in a light-tight, humidified atmosphere of 95% air and 5% CO2 at 37°C.

[0090] Experimental design The study design included five test series of human melanoma A375 cells treated in quintuplicate (five wells per concentration) with solutions at final concentrations of 0, 0.1, 0.3, 1, 3, and 10 μM.

[0091] Human melanoma A375 cells were seeded in 96-well plates (1,500 cells / well) in complete medium (180 μL / well). Prior to cell treatment, solutions (0.74 mM, tubes #0, #1, #4, #24) were diluted with 5% EtOH in sterile water to concentrations of 0, 1, 3, 10, 30, and 100 μM (10 times the final concentration in the cell proliferation assay).

[0092] The day after seeding (day 0), 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide solution was added at the concentrations indicated above (20 μL / well) for 3 days. After 3 days of treatment, cells were fixed with glutaraldehyde and cell viability was quantified using methylene blue.

[0093] An additional plate of A375 cells was fixed with glutaraldehyde on day 0 and stained with methylene blue along with all other plates to quantify cell viability at the start of treatment. Analysis of results was performed by calculating the OD% of the control (no drug) and IC using Prism software. 50 values ​​were calculated.

[0094] Statistical significance of differences between treatments was determined using the 0.3 μM concentration (approximately IC 50 Values ​​were evaluated by one-way ANOVA with Tukey's post hoc HSD test.

[0095] result Exposure of 0.3 mg / mL (0.74 mM) 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide solutions to 1, 4, and 24 hours of sunlight resulted in solutions with increased ratios of cis to trans isomers. Significant inhibition of A375 cell proliferation was detected at all ratios of isomers, showing a dose-dependent effect (Table 4 and Figure 6).

[0096] [Table 4]

[0097] Importantly, samples containing 80–100% trans isomer (no light or 1 h light exposure) had IC 50 The IC value did not change significantly (226–222 nM), but the IC at a cis-to-trans ratio of approximately 50:50 (#4) 50 A significant increase in IC values ​​was observed when the cis to trans ratio increased to approximately 80:20 (753 nM) after 24 h of light exposure and based on the overall compound (cis + trans) assay. 50 Even when the value was normalized (686 nM), the IC 50 There was even a trend towards increasing values. The differences are statistically significant. Thus, these results indicate that interconversion of the trans isomers to the cis-trans mixture is accompanied by a loss of antiproliferative activity, and that the substantially pure trans isomer is a more potent antiproliferative agent.

[0098] The antiproliferative activity of the substantially pure trans isomer versus the cis-trans mixture is further evaluated using the following cell lines: lung cancer: NCI-H1975, head and neck cancer: SCC-9, colon cancer: HCT116, sarcoma: SK-ES.1, hepatocellular carcinoma: HepG2, breast cancer: MDA-MB-468 and MDA-MB-231, multiple myeloma: MM1S and RPMI-8226, ovarian cancer: A2780, gastric cancer: NCI-N87, epidermoid carcinoma: A431, lymphoma: KARPAS, osteosarcoma: Saos2, pancreatic cancer: Panc1, bladder cancer: T24P, glioblastoma: U138MG, prostate cancer: DU145, and leukemia: K562. Cells are exposed to 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide solutions at concentrations of 0, 0.1, 0.3, 1, 3, and 10 μM, containing various cis to trans ratios. Cell proliferation and viability are measured by methylene blue or mitochondrial activity assays (e.g., Cell Titer-Glo, WST-1 assay).

[0099] Example 7: Partition coefficient The octanol:water partition coefficients of the trans and cis isomers of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide were determined. The partition coefficient is an important physical characteristic of a substance that is known to correlate with its ability to be absorbed by tissues. The partition of a pharmaceutical substance provides an assessment of its lipophilicity, which is a major factor that determines the absorption of the substance, its distribution in the body, penetration across vital membranes and biological barriers, metabolism and excretion (ADME properties). LogP (logarithm of the partition coefficient) is an important factor governing passive membrane partitioning, with a direct correlation between LogP and permeability. Furthermore, bioavailability is highly dependent on solubility, permeability, and clearance, which in turn depend on lipophilicity. A LogP in the range of 0 to 3 is considered to result in good bioavailability of the active substance.

[0100] protocol A solution of 10 mM of the trans isomer in DMSO was prepared and diluted 10-fold in water. A solution of the cis isomer was obtained by exposing the trans isomer solution (5 mL) to 125 lux light at 4° C. for 9 hours, resulting in a solution containing more than 90% of the cis isomer. Partitioning in octanol:water was performed as follows: 20 μL of each solution was added to 80 μL of water (saturated with octanol and containing 1 mM ascorbic acid) and 100 μl of octanol (saturated with water). The obtained solution was stirred for 1 minute and left for incubation at room temperature for 24 hours. Each phase was then analyzed by HPLC. Based on the injection volume of each phase and a response factor of 1 (previously measured), a calibration curve was used to determine the concentration (C) of each isomer.

[0101] 7A and 7B show HPLC chromatograms of the cis isomer (approximately 0.1 mM, 1% DMSO) in the octanol and aqueous phases, respectively. The calculated logP(log(C octanol / C water ) was −0.18. Figures 7C and 7D show the HPLC chromatograms of the trans isomer (0.1 mM, 1% DMSO) in the octanol and aqueous phases, respectively. For all relevant analyses, a volume of 13 μL was injected into the HPLC. Because the level of the trans isomer in the aqueous phase was below the limit of quantification (BLQ), a larger volume (35 μL) of the aqueous phase was analyzed in replicates and used to calculate the LogP value using the calibration curve, taking into account the analyzed volume. The calculated logP (log(C octanol / C water )) was 0.86.

[0102] Thus, the logP value of the trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide indicates its improved bioavailability compared to the cis isomer.

[0103] Example 8: Stability in Biorelevant Fluids The stability of the trans- and cis-isomers of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide in biorelevant fluids, including fasted state simulated intestinal fluid (FaSSIF) and fasted state simulated gastric fluid (FaSSGF), was evaluated.

[0104] reagent FaSSIF / FeSSIF / FaSSGF powder (Biorelevant catalog number FFF01) FaSSIF Buffer Concentrate (Biorelevant Catalog No. FASBUF) FaSSGF Buffer Concentrate (Biorelevant Catalog No. FASGBUF)

[0105] protocol A solution containing the cis isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide was prepared by exposing a 5 mL solution of 100% trans isomer at a concentration of 1 mM to 125 lux of light at 4° C. for 9 hours.

[0106] FaSSIF and FaSSGF solutions were prepared according to the manufacturer's instructions.

[0107] Cis and trans isomers of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide were diluted in either FaSSIF or FaSSGF solution to a final concentration of 250 μM. Samples were taken at time 0 and 4 hours later. Samples were frozen in liquid nitrogen and stored frozen until analysis.

[0108] The concentrations of cis and trans isomers at each time point were analyzed by HPLC and the results are summarized in Table 5 and shown in Figures 8A (cis x and trans o) and 8B (cis * and trans o).

[0109] [Table 5]

[0110] Thus, while the trans isomer remained completely stable in FaSSGF, the concentration of the cis isomer was reduced by about 16% (Figure 8A). The same trend was observed in a solution simulating intestinal fluid, but the trans isomer was reduced by only about 7%, and the cis isomer was significantly reduced by about 55% after 4 h (Figure 8B).

[0111] Example 9: Interaction with water molecules Thermogravimetric Analysis (TGA) was used to evaluate the interaction of trans and cis isomers of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide with water molecules.

[0112] TGA was performed on a Perkin Elmer TGA 800 using Pyris software. Temperature scans were performed from 30° C. to 200° C. at a rate of 10° C. / min. Isomers were analyzed at a concentration of 1 mM in water (containing 1% DMSO). The results are summarized in Table 6 and shown in Figures 9A-9C.

[0113] [Table 6]

[0114] While the free water in the cis isomer evaporated at a relatively low temperature, the evaporation of the free water in the trans isomer occurred at significantly higher temperatures, including the onset, intermediate, and end temperatures. The evaporation rate of the free water also showed a significant difference between the cis and trans isomers, whereby the free water in the cis isomer evaporated at a much faster rate (37% / min) than the free water in the trans isomer (23% / min). Without being bound by any theory or mechanism of action, it is believed that the trans isomer does not significantly affect the organization of water, thereby allowing the free adsorbed water to behave in a typical solution-like manner. It is therefore contemplated that the trans isomer exhibits improved stability in aqueous environments compared to the cis isomer, since molecular interactions with water can be correlated with several biological / medical parameters, such as bioavailability, excretion time, and mechanism of dispersion. Thus, the trans isomer is believed to be more bioavailable than the cis isomer.

[0115] While certain particular embodiments of the present invention have been illustrated and described, it will be apparent that the invention is not limited to the embodiments described herein. Numerous modifications, changes, variations, substitutions, and equivalents will be apparent to those skilled in the art without departing from the spirit and scope of the invention, as set forth in the claims that follow.

Claims

1. A substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide having the following structural formula: 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof.

2. 2. The substantially pure trans-isomer of claim 1, comprising at least 80% by weight of the trans-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide and less than 20% by weight of the cis-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide.

3. 2. The substantially pure trans-isomer of claim 1, comprising at least 85% by weight of the trans-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide and less than 15% by weight of the cis-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide.

4. 2. The substantially pure trans-isomer of claim 1, comprising at least 90% by weight of the trans-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide and less than 10% by weight of the cis-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide.

5. 2. The substantially pure trans-isomer of claim 1, comprising at least 95% by weight of the trans-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide and less than 5% by weight of the cis-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide.

6. 2. The substantially pure trans-isomer of claim 1, comprising at least 97% by weight of the trans-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide and less than 3% by weight of the cis-isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide.

7. A pharmaceutical composition comprising as an active ingredient a substantially pure trans isomer according to any one of claims 1 to 6, and a pharma- ceutically acceptable carrier or excipient.

8. 8. The pharmaceutical composition of claim 7 in the form of a solution, suspension, or emulsion.

9. 8. The pharmaceutical composition of claim 7, wherein the pharma- ceutically acceptable carrier or excipient is hydroxypropyl-β-cyclodextrin (HPCD).

10. 10. The pharmaceutical composition of claim 9, wherein the weight ratio between the substantially pure trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-N-(3,4,5-trihydroxy-benzyl)-thioacrylamide or a pharma- ceutically acceptable salt thereof and the HPCD is from about 1:1 to about 1:

12.

11. The pharmaceutical composition according to any one of claims 7 to 10, which is protected from light.

12. 12. The pharmaceutical composition of claim 11, held within a device that is opaque to visible light, said device having a light transmittance within the visible wavelength range of less than about 20%, preferably less than about 10%, more preferably less than about 5%.

13. 12. The pharmaceutical composition of claim 11, stored in a storage container that is opaque to visible light, said storage container having a light transmittance within the visible wavelength range of less than about 20%, preferably less than about 10%, more preferably less than about 5%.

14. 12. The pharmaceutical composition of claim 11, provided in a kit suitable for intravenous administration that is opaque to visible light, said kit having a light transmittance within the visible wavelength range of less than about 20%, preferably less than about 10%, more preferably less than about 5%.

15. 12. The pharmaceutical composition of claim 11, held within a device that is opaque to UV light, said device having a light transmittance within the UV wavelength range of less than about 20%, preferably less than about 10%, more preferably less than about 5%.

16. 12. The pharmaceutical composition of claim 11, stored in a storage container that is impermeable to UV light, said storage container having a light transmittance within the UV wavelength range of less than about 20%, preferably less than about 10%, more preferably less than about 5%.

17. 12. The pharmaceutical composition of claim 11, provided in a kit suitable for intravenous administration that is opaque to UV light, said kit having a light transmittance within the UV wavelength range of less than about 20%, preferably less than about 10%, more preferably less than about 5%.

18. The pharmaceutical composition according to any one of claims 7 to 17 for use in the treatment of cancer.

19. 19. The pharmaceutical composition for use according to claim 18, wherein the cancer is selected from the group consisting of head and neck cancer, sarcoma, multiple myeloma, ovarian cancer, breast cancer, renal cancer, gastric cancer, hematopoietic cancer, lymphoma, leukemia, lung cancer, melanoma, glioblastoma, hepatocellular carcinoma, esophageal cancer, gastroesophageal junction cancer, prostate cancer, pancreatic cancer, and colon cancer.

20. 20. The pharmaceutical composition for use according to claim 18 or 19, wherein the composition is co-administered in combination with an anti-cancer agent.

21. 21. The pharmaceutical composition for use according to claim 20, wherein the anti-cancer agent comprises at least one of: (i) a modulator of a protein kinase (PK) selected from an epidermal growth factor receptor inhibitor (EGFR inhibitor) and an EGFR antibody; (ii) an inhibitor of the mammalian target of rapamycin (mTOR); (iii) a mitogen-activated protein kinase (MEK) inhibitor; (iv) a mutant B-Raf inhibitor; (v) a chemotherapeutic agent; and (vi) an immunotherapeutic agent comprising an antibody against programmed cell death 1 (PD-1) protein, programmed cell death protein 1 ligand (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), or a combination thereof.

22. A method of treating cancer, comprising administering to a subject in need of treatment a substantially pure trans isomer of any one of claims 1 to 6, or a pharmaceutical composition of any one of claims 7 to 17.

23. 23. The method of claim 22, wherein the cancer is selected from the group consisting of head and neck cancer, sarcoma, multiple myeloma, ovarian cancer, breast cancer, renal cancer, gastric cancer, hematopoietic cancer, lymphoma, leukemia, lung cancer, melanoma, glioblastoma, hepatocellular carcinoma, esophageal cancer, gastroesophageal junction cancer, prostate cancer, pancreatic cancer, and colon cancer.

24. 24. The method of claim 22 or 23, comprising co-administering said substantially pure trans isomer or said pharmaceutical composition in combination with an anti-cancer drug.

25. 25. The method of claim 24, wherein the anti-cancer agent comprises at least one of: (i) a protein kinase (PK) modulator selected from an epidermal growth factor receptor inhibitor (EGFR inhibitor) and an EGFR antibody; (ii) an inhibitor of the mammalian target of rapamycin (mTOR); (iii) a mitogen-activated protein kinase (MEK) inhibitor; (iv) a mutant B-Raf inhibitor; (v) a chemotherapeutic agent; and (vi) an immunotherapeutic agent comprising an antibody against programmed cell death 1 (PD-1) protein, programmed cell death protein 1 ligand (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), or a combination thereof.

26. 10. Use of a substantially pure trans isomer according to any one of claims 1 to 6 for the preparation of a medicament for treating cancer.

27. 27. The use of claim 26, wherein the cancer is selected from the group consisting of head and neck cancer, sarcoma, multiple myeloma, ovarian cancer, breast cancer, renal cancer, gastric cancer, hematopoietic cancer, lymphoma, leukemia, lung cancer, melanoma, glioblastoma, hepatocellular carcinoma, esophageal cancer, gastroesophageal junction cancer, prostate cancer, pancreatic cancer, and colon cancer.

28. 28. The use of claim 26 or 27, comprising co-administering the substantially pure trans isomer in combination with an anti-cancer drug.

29. 29. The use of claim 28, wherein the anti-cancer agent comprises at least one of: (i) a protein kinase (PK) modulator selected from an epidermal growth factor receptor inhibitor (EGFR inhibitor) and an EGFR antibody; (ii) an inhibitor of the mammalian target of rapamycin (mTOR); (iii) a mitogen-activated protein kinase (MEK) inhibitor; (iv) a mutant B-Raf inhibitor; (v) a chemotherapeutic agent; and (vi) an immunotherapeutic agent comprising an antibody against programmed cell death 1 (PD-1) protein, programmed cell death protein 1 ligand (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), or a combination thereof.

30. 7. A method for preventing conversion of a substantially pure trans isomer of any one of claims 1 to 6 to a cis isomer, comprising maintaining said substantially pure trans isomer in a light-tight device or container.

31. The method of claim 30, wherein the light blocking device or container is substantially opaque to light in the UV-VIS wavelength range.